Procedural sedation and analgesia for percutaneous high-tech cardiac procedures.


Journal

Minerva cardiology and angiology
ISSN: 2724-5772
Titre abrégé: Minerva Cardiol Angiol
Pays: Italy
ID NLM: 101776555

Informations de publication

Date de publication:
06 2021
Historique:
pubmed: 30 9 2020
medline: 18 9 2021
entrez: 29 9 2020
Statut: ppublish

Résumé

The interest in percutaneous high-tech cardiac procedures has increased in recent years together with its safety and efficacy. In fragile patients, procedural sedation and analgesia are used to perform most of the procedures. General anesthesia remains the technique of choice during the team learning curve and might be required in selected patients or in emergent situations. Despite the high costs of percutaneous high-tech cardiac procedures, the decrease in length of hospital stays, rate of intensive care admission and complications, balance the increase in devices costs. In fragile patients who undergo percutaneous high tech cardiac procedures, the primary role of the anesthesiologist is to prevent the need for postprocedural intensive care unit and complications rate. Starting from the experience of a large university third level hospital we identified the eight most commonly performed contemporary percutaneous high tech cardiac procedures (ventricular tachycardia and atrial fibrillation ablation, protected percutaneous coronary intervention, transcatheter aortic valve implantation, MitraClip® (Abbott Laboratories; Abbott Park, IL, USA), percutaneous patent foramen ovale closure, left atrial appendage closure, and dysfunctional lead extraction), discuss the role of procedural sedation and analgesia in this setting, and explore future perspectives.

Identifiants

pubmed: 32989964
pii: S0026-4725.20.05211-1
doi: 10.23736/S2724-5683.20.05211-1
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

358-369

Auteurs

Alberto Zangrillo (A)

IRCCS San Raffaele Scientific Institute, Milan, Italy.
IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy.

Federica Morselli (F)

IRCCS San Raffaele Scientific Institute, Milan, Italy.

Gaetano Lombardi (G)

IRCCS San Raffaele Scientific Institute, Milan, Italy.

Andrey Yavorovskiy (A)

Department of Anesthesiology and Intensive Care, First Moscow State Medical University, Moscow, Russia.

Valery Likhvantsev (V)

V. Negovsky Reanimatology Research Institute, Moscow, Russia.

Luigi Beretta (L)

IRCCS San Raffaele Scientific Institute, Milan, Italy.
IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy.

Fabrizio Monaco (F)

IRCCS San Raffaele Scientific Institute, Milan, Italy.

Giovanni Landoni (G)

IRCCS San Raffaele Scientific Institute, Milan, Italy - landoni.giovanni@hsr.it.
IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH